vcn-01 oncolytic adenovirus
vcn-01 oncolytic adenovirus: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Theriva Biologics, Inc. (TOVX)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Theriva Biologics, Inc. (TOVX) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase IIa, Single-arm, Single-center, Open Label, Proof-of-concept Trial Evaluating Increased Frequency Dosing of VCN-01 (Zabilugene Almadenorepvec) in Combination With Nab-Paclitaxel/Gemcitabine (GnP) in Patients With Newly-Diagnosed Metastatic Pancreatic Cancer
Frequently asked questions
Who is developing vcn-01 oncolytic adenovirus?
vcn-01 oncolytic adenovirus is being developed by Theriva Biologics, Inc..
How many clinical trials involve vcn-01 oncolytic adenovirus?
BioSniper tracks 1 clinical trial involving vcn-01 oncolytic adenovirus.
Analyze Theriva Biologics, Inc. & vcn-01 oncolytic adenovirus with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company